- Home
- FLNC vs ARVN Comparison
FLNC vs ARVN Comparison
Compare FLNC & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLNC
- ARVN
- Stock Information
- Founded
- FLNC 2018
- ARVN 2015
- Country
- FLNC United States
- ARVN United States
- Employees
- FLNC N/A
- ARVN N/A
- Industry
- FLNC Industrial Machinery/Components
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- FLNC Miscellaneous
- ARVN Health Care
- Exchange
- FLNC Nasdaq
- ARVN Nasdaq
- Market Cap
- FLNC 533.2M
- ARVN 456.2M
- IPO Year
- FLNC 2021
- ARVN 2018
- Fundamental
- Price
- FLNC $5.83
- ARVN $7.44
- Analyst Decision
- FLNC Buy
- ARVN Buy
- Analyst Count
- FLNC 18
- ARVN 21
- Target Price
- FLNC $9.03
- ARVN $20.53
- AVG Volume (30 Days)
- FLNC 4.0M
- ARVN 2.3M
- Earning Date
- FLNC 08-06-2025
- ARVN 07-29-2025
- Dividend Yield
- FLNC N/A
- ARVN N/A
- EPS Growth
- FLNC N/A
- ARVN N/A
- EPS
- FLNC N/A
- ARVN N/A
- Revenue
- FLNC $2,329,871,000.00
- ARVN $426,900,000.00
- Revenue This Year
- FLNC $3.61
- ARVN $4.26
- Revenue Next Year
- FLNC $25.79
- ARVN N/A
- P/E Ratio
- FLNC N/A
- ARVN N/A
- Revenue Growth
- FLNC 6.08
- ARVN 498.74
- 52 Week Low
- FLNC $3.46
- ARVN $5.90
- 52 Week High
- FLNC $24.00
- ARVN $34.11
- Technical
- Relative Strength Index (RSI)
- FLNC 67.78
- ARVN 51.46
- Support Level
- FLNC $4.68
- ARVN $7.12
- Resistance Level
- FLNC $5.98
- ARVN $7.85
- Average True Range (ATR)
- FLNC 0.37
- ARVN 0.43
- MACD
- FLNC 0.10
- ARVN 0.05
- Stochastic Oscillator
- FLNC 78.16
- ARVN 48.05
About FLNC Fluence Energy Inc.
Fluence Energy Inc is enabling the global clean energy transition with market-leading energy storage products and services, and digital applications for renewables and storage. Geographically, it derives a majority of its revenue from the Americas.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.